CardioHub - CardioBites+ Amyloidosis

Overview - What are CardioBites+

Building on the success of the CardioBites Series, the CardioBites + Video Series is designed to take learning to the next level, offering expanded microlearning content that is both accessible and impactful for physicians, scientists, nurses, nurse practitioners, pharmacists, and patients about the recent advances and emerging trends in heart failure. They can be watched anytime, anywhere on YouTube. No password. No barriers. Just easy access.

CardioBites+ Amyloidosis Series

Amyloidosis: Mechanism of Disease. The majority of cardiac amyloidosis is caused by 2 proteins and is classified as either amyloid light-chain (AL) amyloidosis or transthyretin amyloidosis (ATTR). Join us for this discussion of the different mechanisms of disease and why understanding these differences may impact management decisions for these patients. Watch now!

Amyloidosis: Diagnosis. Cardiac amyloidosis remains underrecognized and underdiagnosed, despite its increasing prevalence and significant impact on heart failure outcomes. Its heterogeneous presentation, ranging from heart failure with preserved ejection fraction (HFpEF) to peripheral neuropathy or unexplained LV thickening, can mask the underlying cause and delay intervention. Watch now!

In this CardioBites+ video, we’ll break down the key clinical clues that should raise suspicion for cardiac amyloidosis. Learn how to identify the red flags in your patients, distinguish between AL and ATTR types, and apply the latest diagnostic approaches, including imaging, biomarker assessment, and tissue biopsy. Early detection can dramatically influence treatment strategies and patient prognosis—don’t miss this essential discussion.

Amyloidosis: Treatment/Management. Amyloidosis is a serious condition caused by the buildup of abnormal, insoluble amyloid fibrils within the tissues and organs. The two most common forms associated with cardiac complications are immunoglobulin light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis. Patients may present with heart failure with preserved ejection fraction (HFpEF) or develop restrictive cardiomyopathy, leading to significant functional impairment.

In this CardioBites+ video, we explore the role of disease-modifying treatments as well as non-disease-modifying therapies for patients with cardiac amyloidosis. Watch now!

Subscribe to HFSA on YouTube

CardioBites+ FAQs

Please visit our post-module evaluation survey as well!

Visit our website: https://hfsa.org/cardiobites+

Supporter(s)

The Heart Failure Society of America acknowledges Alnylam Pharmaceuticals for providing an independent grant to support the HFSA CardioBites+: Amyloidosis series.

Summary

Availability:

On-Demand

Cost:

FREE

Credit Offered:

No Credit Offered

Create Account